NeoPharm Sets Conference Call and Webcast for First Quarter Corporate Results.
WAUKEGAN Waukegan (wôkē`gən), residential and industrial city (1990 pop. 69,392), seat of Lake co., NE Ill., on Lake Michigan; inc. 1859. It has a good harbor and is the first port of call in Illinois on the St. Lawrence Seaway route. , Ill. -- NeoPharm, Inc. (Nasdaq:NEOL) today announced the date and time for its regularly-scheduled quarterly conference call to discuss corporate developments and financial highlights for the first quarter ended March 31, 2006.
The conference call will be held on:
Friday, May 5, 2006 at 11:00 a.m. Eastern/8:00 a.m. Pacific ----------------------------------------------------------- Domestic: 800-688-0836, passcode 45361215 International: 617-614-4072, passcode 45361215 Audio replays will be available through May 12, 2006. Domestic: 888-286-8010, passcode 61152573 International: 617-801-6888, passcode 61152573
The live call and replay will also be available via webcast at www.neopharm.com.
NeoPharm's Commitment to Oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors.
NeoPharm employees share a common goal: bringing hope to cancer patients and their families through the research and development of new cancer drugs and therapies. The Company's oncology portfolio is built on two novel, proprietary platforms: a tumor-targeting platform, and the NeoLipid(R) Liposomal Drug Delivery platform. Through its research and clinical studies, as well as its work with physicians, scientists, and advocacy The act of Pleading or arguing a case or a position; forceful persuasion. groups, NeoPharm is helping to enhance the lives of cancer patients.
About NeoPharm, Inc.
NeoPharm, Inc., based in Waukegan, Illinois Waukegan (IPA: /wɔˈkiːgən/) is a city in Lake County, Illinois. As of the 2000 census, the city had a total population of 87,901. Estimated population in 2006: 93,389 . , is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NeoPharm's Web site at www.neopharm.com.
Forward Looking Statements - This press release contains "forward-looking statements forward-looking statement
A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to relating to relate prep → concernant
relating to relate prep → bezüglich +gen, mit Bezug auf +acc the Company's drug development program, including, but not limited to clinical trials including cintredekin besudotox, future patient survival in the Company's ongoing Phase I/II studies and PRECISE trial, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, development, testing, obtaining regulatory reg·u·late
tr.v. reg·u·lat·ed, reg·u·lat·ing, reg·u·lates
1. To control or direct according to rule, principle, or law.
2. approval, production and marketing of the Company's drug and non-drug compounds, including, but not limited to, cintredekin besudotox, uncertainty regarding the availability of third party production capacity, unexpected adverse side effects Side effects
Effects of a proposed project on other parts of the firm. or inadequate therapeutic efficacy efficacy /ef·fi·ca·cy/ (ef´i-kah-se)
1. the ability of an intervention to produce the desired beneficial effect in expert hands and under ideal circumstances.
2. of the Company's drug and non-drug compounds, including, but not limited to, cintredekin besudotox, that could slow or prevent products coming to market, uncertainty regarding the Company's ability to market its drug and non-drug products, including, but not limited to, cintredekin besudotox, directly or through independent distributors, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, cintredekin besudotox, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual reports on Form 10-K Form 10-K
A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information.
See 10-K. and quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction "Prediction is very difficult, especially if it's about the future." - Niels Bohr
A prediction is a statement or claim that a particular event will occur in the future in more certain terms than a forecast. of actual future results.